Adam Cutler

Adam Cutler, Chief Financial Offer of Q32 Bio, has more than 20 years of experience in corporate finance, business development, investment banking, equity research, investor relations, and management consulting. Prior to joining Q32 Bio, Adam served as Chief Financial Officer of Molecular Templates where he was instrumental in building the company, including leading efforts to raise approximately $300 million in capital. Previously, he was Senior Vice President of Corporate Affairs at Arbutus Biopharma, where his responsibilities included investor relations, business development, and corporate finance. He was also a Managing Director for The Trout Group and Trout Capital, where he executed financings and advised life science companies on investor relations, capital raising, and business development. Earlier in his career, Adam was a biotechnology equity research analyst at Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Securities. He also worked in healthcare consulting at The Frankel Group and Ernst & Young LLP. He currently serves on the Board of Directors for InMed Pharmaceuticals and previously served on the Board of Directors for Navidea Biopharmaceuticals. He received his Bachelor of Arts in Economics from Brandeis University.